{"filing":{"accession_number":"0001193125-26-232717","cik":"0001583648","ticker":"PVLA","company_name":"PALVELLA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-05-20","report_date":null,"primary_document":"pvla-20260520.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583648/000119312526232717/pvla-20260520.htm"},"events":[{"id":9814,"run_id":8606,"accession_number":"0001193125-26-232717","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces positive Phase 3 and Phase 2 clinical trial data presented at a major medical congress. While this represents material clinical progress for a biopharmaceutical company that could affect investor assessment of pipeline value and regulatory prospects, it does not fit the earnings_release category (which typically applies to financial results) nor any other more specific event type. The clinical data announcement is material but best classified as other_material given the taxonomy's focus on financial and corporate governance events.","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-05-20","form":"8-K","submitted_at":null,"items":[{"id":621,"accession_number":"0001193125-26-232717","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces positive Phase 3 and Phase 2 clinical trial data presented at a major medical congress. While this represents material clinical progress for a biopharmaceutical company that could affect investor assessment of pipeline value and regulatory prospects, it does not fit the earnings_release category (which typically applies to financial results) nor any other more specific event type. The clinical data announcement is material but best classified as other_material given the taxonomy's focus on financial and corporate governance events.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:48:29.441172+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":621,"accession_number":"0001193125-26-232717","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces positive Phase 3 and Phase 2 clinical trial data presented at a major medical congress. While this represents material clinical progress for a biopharmaceutical company that could affect investor assessment of pipeline value and regulatory prospects, it does not fit the earnings_release category (which typically applies to financial results) nor any other more specific event type. The clinical data announcement is material but best classified as other_material given the taxonomy's focus on financial and corporate governance events.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-21T02:48:29.441172+00:00","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-05-20"}]}